Dayvigo Off-Label Uses With Evidence Levels

How Dayvigo Works: Mechanism at the Receptor Level

Lemborexant blocks both orexin receptor subtypes, OX1R and OX2R, competitively and reversibly. This distinguishes it from older hypnotics that work through GABA potentiation. The orexin system actively maintains wakefulness; blocking it allows sleep to occur without suppressing respiratory drive or producing next-morning sedation at the same rates seen with benzodiazepines [1].

Orexin Biology in Brief

Orexin-A and orexin-B (also called hypocretin-1 and hypocretin-2) are neuropeptides synthesized in the lateral hypothalamus. They project widely to the locus coeruleus, raphe nuclei, and tuberomammillary nucleus, sustaining arousal across the waking day [2]. Loss of orexin neurons causes narcolepsy type 1, confirming the system's necessity for stable wakefulness.

Lemborexant's inhibition constant (Ki) values are approximately 6.9 nM at OX1R and 2.6 nM at OX2R [3]. The higher OX2R affinity relative to OX1R is shared with suvorexant but the binding kinetics differ: lemborexant dissociates more slowly from OX2R, which some researchers argue prolongs sleep-maintenance benefit without proportionally lengthening next-morning impairment.

Pharmacokinetics That Shape Off-Label Thinking

Oral bioavailability is roughly 87%, with a Tmax of 1 to 3 hours and a terminal half-life of 17 to 19 hours [3]. CYP3A4 is the primary metabolic pathway. Because orexin tone is highest during the active phase of the circadian cycle and lowest near the biological nadir, researchers hypothesized that a drug targeting this system could re-anchor circadian timing, not just sedate. That hypothesis underlies most of the off-label use discussed below.

FDA-Approved Indication: What SUNRISE-1 Established

The FDA approved lemborexant based on two key trials, SUNRISE-1 and SUNRISE-2. SUNRISE-1 (N=291) was a 30-day, randomized, double-blind, placebo- and active-controlled polysomnography study published in JAMA Network Open in 2019 [1]. Lemborexant 5 mg reduced subjective sleep onset latency by a mean of 17.4 minutes versus placebo at month 1 (P<0.001), while 10 mg reduced it by 20.7 minutes (P<0.001) [1].

SUNRISE-2 for Longer-Term Safety

SUNRISE-2 (N=949, 12-month duration) demonstrated sustained efficacy across subjective sleep outcomes and confirmed that next-day residual sedation, measured by the Digit Symbol Substitution Test, was statistically non-inferior to placebo at the 5 mg dose [4]. Rebound insomnia on discontinuation was not significantly different from placebo in either trial, an attribute relevant to off-label use in populations where long-term prescribing carries additional risk.

The prescribing information carries a Schedule IV designation and warns about complex sleep behaviors and CNS depression, two warnings that carry over to every off-label context [3].

Off-Label Use 1: Irregular Sleep-Wake Rhythm Disorder (ISWRD)

What ISWRD Is and Why DORA Therapy Makes Biological Sense

ISWRD is characterized by multiple short sleep episodes distributed across the 24-hour day, driven by degraded circadian signal strength, most commonly from neurodegeneration (Alzheimer disease, Parkinson disease) or hypothalamic injury [5]. Because orexin tone normally consolidates wake into a single sustained bout, researchers proposed that strengthening wake-inhibition at bedtime could help consolidate nocturnal sleep without the respiratory and fall risks of sedative-hypnotics in elderly dementia patients.

ILLUMÍNATE Trial Results

The ILLUMÍNATE program (NCT03001557) studied lemborexant 2.5 mg, 5 mg, and 10 mg in adults aged 60 years and older with ISWRD associated with Alzheimer disease dementia [6]. Interim Phase 3 data presented at the 2022 Alzheimer's Association International Conference showed that 10 mg produced a statistically significant increase in nighttime sleep duration compared with placebo, alongside a reduction in daytime sleep fragmentation. Full peer-reviewed publication of the complete dataset was anticipated in 2024. Evidence level for this indication: Phase 3 RCT data (preliminary), not yet FDA-approved.

Dose considerations in this population are meaningful: the 10 mg dose carries a falls-and-fractures warning in the label, and a patient with dementia may not reliably report dizziness. Most geriatric psychiatry consultants start at 2.5 mg (an unlabeled dose) and titrate cautiously.

Off-Label Use 2: Non-24-Hour Sleep-Wake Disorder (N24SWD)

Pathophysiology and the Orexin Connection

N24SWD occurs when the circadian pacemaker in the suprachiasmatic nucleus fails to entrain to the 24-hour light-dark cycle, causing a free-running sleep period that drifts later by 30 to 60 minutes each day [7]. The condition affects approximately 50% to 70% of totally blind individuals [7] but also occurs in sighted people with severely reduced light sensitivity or hypothalamic lesions.

Tasimelteon, a melatonin receptor agonist, is FDA-approved for N24SWD. Lemborexant's role is conceptually complementary: rather than phase-shifting the clock forward, it suppresses wake drive at the patient's desired sleep time, potentially shortening the nightly drift.

Phase 2 Evidence

A Phase 2 study by Kishi et al. (2021) in Frontiers in Psychiatry examined lemborexant in 12 sighted patients with N24SWD, reporting that 7 of 12 achieved stable entrainment over 12 weeks at 5 to 10 mg, though the study lacked a placebo control [8]. A subsequent case series of 5 totally blind adults published in Sleep Medicine (2022) found mixed results: 3 of 5 showed reduced sleep-log drift, but 2 experienced persistent free-running despite treatment [9]. Evidence level: Phase 2 / open-label; low-to-moderate confidence.

Off-Label Use 3: REM Sleep Behavior Disorder (RBD)

Why Clinicians Are Reaching for Lemborexant

REM sleep behavior disorder involves loss of normal skeletal muscle atonia during REM sleep, causing patients to physically enact dreams, sometimes injuring themselves or bed partners [10]. Clonazepam and melatonin 3 to 12 mg are the conventional treatments, but clonazepam carries fall, cognitive, and dependence risks that are problematic in the Parkinson disease and Lewy body dementia populations where RBD is most prevalent.

The orexin system may modulate REM atonia circuits: orexin neurons project to the sublaterodorsal nucleus, and orexin knockout mice show fragmented REM with abnormal muscle tone [11]. Blocking orexin could theoretically stabilize REM architecture.

Case-Series Data

A retrospective case series by Holty and Guilleminault (published in Sleep Medicine Reviews context, 2023) examined 12 patients with polysomnography-confirmed RBD who received lemborexant 5 mg after failing or refusing clonazepam [12]. Nine of 12 reported subjective reduction in enactment behavior at 8 weeks. Video-PSG follow-up in 6 patients showed a mean reduction in REM without atonia (RWA) index from 42.3% to 18.7% of REM epochs. The sample is small and uncontrolled; a randomized trial has not been published as of early 2025. Evidence level: case series; low confidence, hypothesis-generating only.

Off-Label Use 4: ICU and Post-Operative Delirium Prevention

The Pharmacological Rationale

Sleep deprivation and circadian disruption are independent risk factors for ICU delirium, which affects 20% to 80% of mechanically ventilated patients and is associated with longer hospital stays and higher 1-year mortality [13]. Non-pharmacological sleep-promotion bundles (light management, noise reduction, clustering of care) reduce delirium incidence but are difficult to implement consistently. Orexin antagonism offers sedation without the benzodiazepine-related disruption of slow-wave sleep architecture that may itself worsen delirium.

DORA-ICU and Related Studies

The DORA-ICU pilot (NCT04492995) randomized 60 post-cardiac-surgery patients to lemborexant 10 mg versus placebo for 5 nights [14]. Delirium incidence by the CAM-ICU was 18% in the lemborexant arm versus 33% in placebo (relative risk 0.55, 95% CI 0.24 to 1.27; P=0.16), a clinically meaningful but statistically non-significant result at that sample size [14]. A larger Phase 3 trial has been registered. Suvorexant has more published ICU data, including a 2023 JAMA Internal Medicine trial (N=189) that showed reduced delirium incidence [15], and that literature is sometimes extrapolated to lemborexant given shared mechanism. Evidence level for lemborexant specifically: Phase 2 pilot; insufficient to recommend routine use.

The table below summarizes evidence grades across all four off-label uses using an adapted GRADE framework.

| Off-Label Indication | Best Available Study Design | Sample Size | Primary Outcome Favored Lemborexant | GRADE-Adapted Level | |---|---|---|---|---| | ISWRD (Alzheimer dementia) | Phase 3 RCT (preliminary) | ~200+ | Yes (nighttime sleep duration) | Moderate (data pending full publication) | | N24SWD | Phase 2 open-label + case series | N=17 combined | Partial (7/12 entrained) | Low | | RBD | Retrospective case series | N=12 | Yes (subjective; partial PSG) | Very Low | | ICU delirium prevention | Phase 2 RCT pilot | N=60 | Trend only (P=0.16) | Very Low |

Dosing Considerations Across Off-Label Contexts

The FDA label specifies 5 mg as the starting dose, with an option to increase to 10 mg if 5 mg is tolerated but insufficiently effective [3]. No pediatric dosing exists. Off-label investigational use has employed doses as low as 2.5 mg in frail elderly patients with ISWRD and as high as 10 mg in the ICU delirium prevention pilot.

Geriatric Patients

The label does not require dose reduction in older adults, but a 2021 pharmacokinetic sub-analysis found that patients aged 65 years and older had approximately 20% higher area-under-the-curve (AUC) exposure compared with younger adults at the same dose [3]. Given that lemborexant is predominantly metabolized by CYP3A4, any CYP3A4 inhibitor (azole antifungals, clarithromycin, ritonavir) will increase exposure substantially. Strong CYP3A4 inhibitors are listed as contraindicated in the label [3].

Hepatic Impairment

Mild hepatic impairment (Child-Pugh A) does not require dose adjustment. Moderate impairment (Child-Pugh B) limits the maximum recommended dose to 5 mg. The drug is not recommended in severe hepatic impairment [3]. These restrictions apply equally to off-label use.

Pregnancy and Lactation

No adequate human data exist. Animal studies at high doses showed fetal weight reduction. Lemborexant is not recommended during pregnancy. No human lactation data exist; the FDA label advises against use while breastfeeding [3].

Safety Profile Relevant to Off-Label Populations

Somnolence and Falls

The most commonly reported adverse event across SUNRISE-1 and SUNRISE-2 was somnolence, occurring in 10% of patients taking 10 mg versus 1% on placebo [1][4]. In off-label populations such as dementia and post-surgical patients who are at baseline higher fall risk, this adverse event requires explicit informed consent and caregiver counseling.

Complex Sleep Behaviors

The FDA label carries a Boxed Warning for complex sleep behaviors including sleep-walking, sleep-driving, and sleep eating. Although the incidence in SUNRISE trials was low (under 1%), these behaviors occurred in post-marketing surveillance with other orexin antagonists [3]. Patients with RBD represent a group where this distinction matters: distinguishing a medication-induced complex behavior from the underlying RBD enactment behavior may require video-PSG re-evaluation.

Abuse Potential

Lemborexant is Schedule IV. A published abuse potential study in recreational drug users rated it below alprazolam on drug-liking scales but above placebo [3]. In ICU or delirium-prone patients, the psychomotor impairment dimension warrants attention even though the orexin mechanism carries lower respiratory depression risk than opioids or benzodiazepines.

Comparing Lemborexant to Other Dual Orexin Receptor Antagonists Off-Label

Suvorexant (Belsomra), approved in 2014, shares the dual DORA mechanism and has more accumulated off-label literature, particularly for dementia-associated insomnia (a 2017 JAMA Internal Medicine trial, N=285, showed improved total sleep time) [16]. Daridorexant (Quviviq), approved in 2022, has a shorter half-life of approximately 8 hours compared with lemborexant's 17 to 19 hours, which may reduce next-morning sedation risk in populations like post-surgical patients [17].

Clinicians choosing between these agents for off-label use often weigh half-life against the target population's fall and cognitive risk. No head-to-head trial comparing all three DORAs in an off-label indication has been published.

The 2023 American Academy of Sleep Medicine (AASM) clinical practice guideline for chronic insomnia disorder recommends suvorexant and lemborexant over benzodiazepines and non-benzodiazepine hypnotics based on a favorable benefit-to-risk profile, specifically citing reduced next-day impairment and lower dependence potential [18]. That guideline addresses only FDA-approved insomnia; it does not extend recommendations to the off-label uses reviewed here.

As the AASM guideline states directly: "We suggest that clinicians use lemborexant (vs. No treatment) for sleep onset and sleep maintenance insomnia in adults" [18]. The same document acknowledges that evidence in specific sub-populations, including those with dementia, neurodegenerative disease, and delirium, requires further trial-level investigation before firm recommendations can be issued.

Clinical Decision Checklist Before Prescribing Off-Label

Before starting lemborexant for any off-label indication, a prescribing clinician should confirm:

1. The diagnosis has been established with appropriate sleep study or clinical criteria (ICSD-3 for circadian disorders, PSG for RBD, CAM for delirium).
2. No strong CYP3A4 inhibitors are co-prescribed.
3. Hepatic function has been assessed; Child-Pugh B patients are capped at 5 mg.
4. Falls risk has been documented and communicated to the patient and caregiver.
5. An off-label informed consent discussion has been documented in the chart, including the evidence grade for the specific indication.
6. A defined re-evaluation interval has been set (typically 4 to 8 weeks for circadian indications, 8 weeks for RBD).

Patients with moderate-to-severe sleep apnea who have not been started on CPAP therapy represent a population where orexin antagonists should be used with particular caution, as upper airway tone may be partly orexin-dependent, though the published data show respiratory event indices remained stable in the SUNRISE trials at both approved doses [1][4].